Skip to main content
Premium Trial:

Request an Annual Quote

Betty Woods, John Wareham, Joseph Fernandez, Harry Beaty, Frank Olson, John Pouk, Joseph Sorge, Nicolas Roelofs, Nelson Thune, Mary Joanne Deal, Peter Tunon, Thomas Guiel, Rok Sribar, Kenneth Langone

Betty Woods has been named non-executive chairman of the board of directors for Beckman Coulter, effective April 7 at the company’s stockholder’s meeting. She will succeed John Wareham, who is retiring, the company said this week.

Woods, former president and CEOof Premera Blue Cross (formerly Blue Cross of Washington and Alaska) and chief executive officer of Premara, the holding company of Premera Blue Cross, has been a member of the Beckman Coulter board since 1994. She currently chairs the board’s organization and compensation committees.

Woods is on the board of trustees of Western Washington University and Seattle University, and is a founding member of the National Institute for Health Care Management.

Joseph Fernandez, president of Active Motif, a Carlsbad, Calif., biotech firm specializing in cell and molecular biology research, has been named to the California Economic Strategy Panel. Fernandez formerly worked for Stratagene Cloning, Scripps Clinic, and Invitrogen.

Harry Beaty and Frank Olson have reached Becton Dickinson’s mandatory retirement age and have retired from BD’s board of directors, the company said in an SEC filing. Additionally, at the company’s annual meeting, BD shareholders elected Basil Anderson, Gary Mecklenburg, James Perrella, and Alfred Sommer to the board for three-year terms.

Stratagene amended its Sept. 1, 2002, employment agreement with John Pouk, senior vice president of global sales and international operations, the company said in an SEC filing. The company terminated an option to purchase shares of common stock previously granted to Pouk, and changed his eligibility for a bonus that was previously determined. Beginning with the company’s 2004 fiscal year, Pouk’s annual performance bonus is subject to review by the board of directors and shall be determined and adjusted at the sole discretion of the board, the company said. He was granted a bonus of $42,123.64 for 2004.

Additionally, Stratagene paid Joseph Sorge, chairman, CEO, and president of the company, a bonus of $90,000; Reginald Jones, senior vice president and chief financial officer, $65,000; Ronni Sherman, executive vice president and general counsel, $63,666.68; Nicolas Roelofs, former chief operating officer $57,260.83; Nelson Thune, senior vice president of operations, $45,924.24; and Mary Joanne Deal, Hycor senior vice president for marketing and sales, $40,952.

Peter Tunon has been named president and Thomas Guiel chief operating officer of Cellectricon’s new wholly owned US subsidiary of the same name, the company said last week. The subsidiary will be headquartered in Gaithersburg, Md. Tunon previously was a manager at Bio-Rad Laboratories, Invitrogen Life Technologies, and GraceVydac; and Guiel previously was responsible for establishing manufacturing, ordering, and distribution operations worldwide at Invitrogen.

Rok Sribar joins Align Technology of Santa Clara, Calif., as vice president of research and development, the company said this week. Sribar was vice president at Symbol Technologies and previously worked for General Electric in corporate R&D, and in the medical systems unit.

Kenneth Langone, co-founder of Home Depot, will not seek re-election to the board of directors of General Electric, according to news reports. Langone is being sued by NY Attorney General Eliot Spitzer over his role in a New York Stock Exchange compensation scandal.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.